Journal
BLOOD
Volume 125, Issue 21, Pages 3347-3350Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-10-608315
Keywords
-
Categories
Funding
- Hamburger Krebshilfe Foundation
- Roggenbuck Foundation
- National Institutes of Health, National Heart, Lung, and Blood Institute [HL084054, HL036444]
- National Cancer Institute [CA018029, CA015704]
- Associazione Italiana per la Ricerca sul Cancro
- Special Program Molecular Clinical Oncology 5 x 1000 project [1005]
- Instituto de Salud Carlos III, Spanish Ministry of Health [RD012/0036/0004]
- Associazione Italiana Leucemie-Onlus Varese
Ask authors/readers for more resources
Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on its net advantage over conventional therapies is lacking. Using ad hoc statistical analysis, we determined outcomes in 438 patients <65 years old at diagnosis who received allogenic SCT (n = 190) or conventional therapies (n = 248). Among patients at low risk per the Dynamic International Prognostic Scoring System (DIPSS) model, the relative risk of death after allogenic SCT vs those treated with nontransplant modalities was 5.6 (95% CI, 1.7-19; P = .0051); for intermediate-1 risk it was 1.6 (95% CI, 0.79-3.2; P = .19), for intermediate-2 risk, 0.55 (95% CI, 0.36-0.83; P = .005), and for high risk, 0.37 (95% CI, 0.21-0.66; P = .0007). Thus, patients with intermediate-2 or high-risk PMF clearly benefit from allogenic SCT. Patients at low risk should receive nontransplant therapy, whereas individual counseling is indicated for patients at intermediate-1 risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available